Drug Trial Radar · NCT06450106
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
Last checked: Nov 19, 2026Latest source record: Feb 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
18
Planned (sponsor's estimate)
Start
May 8, 2025
Primary completion
Sep 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- SURGE TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 10, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy
Conditions
- Prostate Cancer
Interventions
STM-416pDrug
STM-416p monotherapy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]Time frame: 21 Days
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: Time on trial up to 90 days
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
Arizona Urology Specialists
Tucson, Arizona · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Australian Prostate Center
Melbourne N., Victoria, Australia · Recruiting
Epworth HealthCare
Melbourne N., Victoria, Australia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.